Skip to main content
Kenneth Murray, MD, Neurology, Cullman, AL

Kenneth R Murray MD

Sleep Medicine


Assistant Clinical Professor of Neurology, SUNY Buffalo

Join to View Full Profile
  • 1890 AL Highway 157Ste 102Cullman, AL 35058

  • Phone+1 256-903-0300

  • Fax+1 256-801-7893

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Kenneth Murray, MD is a board certified neurologist in Cullman, Alabama. He is currently licensed to practice medicine in Alabama, Nebraska, and Texas. He is an Assistant Clinical Professor of Neurology at SUNY Buffalo.

Education & Training

  • University at Buffalo
    University at BuffaloResidency, Neurology, 1983 - 1987
  • Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
    Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1983

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2023 - 2025
  • NY State Medical License
    NY State Medical License 1984 - 2025
  • NE State Medical License
    NE State Medical License 2021 - 2024
  • TX State Medical License
    TX State Medical License 1987 - 1988
  • Neurology
    American Board of Psychiatry and Neurology Neurology

Press Mentions

  • Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
    Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) CongressOctober 17th, 2022
  • Sage Therapeutics and Biogen Announce That the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met Its Primary and All Key Secondary Endpoints
    Sage Therapeutics and Biogen Announce That the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met Its Primary and All Key Secondary EndpointsJune 1st, 2022
  • How Doctors Die
    How Doctors DieDecember 13th, 2018